Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Overview of attention for article published in New England Journal of Medicine, December 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 80 news outlets
blogs: 7 blogs
policy: 4 policy sources
twitter: 338 X users
patent: 136 patents
facebook: 15 Facebook pages

googleplus: 2 Google+ users
reddit: 6 Redditors
q&a: 1 Q&A thread
video: 1 YouTube creator
guideline: 12 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 3470 Mendeley
citeulike: 3 CiteULike

So far, Altmetric has seen 472 X posts from 338 X users, with an upper bound of 3,850,594 followers.

論文張っときます https://t.co/GR9QW7EKnw

@mimic_josler 10/15の発生率であればCAR-Tで起こるCRSとしてはそこまで多い訳でもない範囲です。ICANSもあまり起きてないので安全性は悪くないかもです。参考までにAxi-celというDLBCLなどに保険が通ってるCAR-Tのはじめての試験（zuma-1）とかでも8割起きてたりします。 …

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma https://t.co/9V5MzyQbs8

RT @marklewismd: Easily one of the most satisfying images I’ve ever seen in oncology: an otherwise-refractory large B-cell lymphoma with co…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 468 additional X posts.